Corbus Pharmaceuticals Holding

Corbus Pharmaceuticals announced positive results from its phase Ib CANYON-1 study of CRB-913, an oral cannabinoid-based small molecule for obesity, with once-daily treatment achieving statistically significant and clinically meaningful weight loss across all three dose levels at 12 weeks. The 20-mg and 40-mg doses delivered placebo-adjusted mean weight loss of 2.8% and 3.3%, respectively, while the 60-mg dose achieved 5%, with no evidence of a weight-loss plateau at any dose. Corbus said treatment discontinuations due to adverse events were lower than those reported for approved oral GLP-1 drugs such as Eli Lilly's Foundayo and Novo Nordisk's Wegovy pill, and that preclinical studies showed CRB-913 was 15 times more peripherally restricted than Novo Nordisk's monlunabant, which Novo discontinued in the second quarter of 2026. Detailed CANYON-1 results are expected at ObesityWeek 2026 in November, and Corbus intends to engage with the FDA on a clinical plan to advance CRB-913 to phase II development. Beyond the obesity candidate, Corbus has an oncology program in CRB-701, a Nectin-4-targeting antibody-drug conjugate that the FDA has cleared for the registrational phase III TEMPO-1 study in second-line oropharyngeal squamous cell carcinoma, with enrollment expected to start later this month. Corbus had about $118 million in cash, cash equivalents and investments as of June 30, 2026, which it expects to support operations into 2028.